Phase IIIb Comparison of BARACLUDE
Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy versus BARACLUDE plus Tenofovir Combination Shows No Statistical Difference Between Study Arms
San Francisco, CA (PRWEB) November 09, 2011
Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week results from the BE‐LOW™ study, a Phase IIIb clinical trial comparing BARACLUDE monotherapy (0.5mg once daily) with BARACLUDE (0.5mg once daily) plus tenofovir (300mg once daily) in treatment-naïve adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) with compensated liver disease. In this study, no statistically significant difference was observed between the two treatment arms in the primary efficacy endpoint of HBV DNA
“In these 96-week data comparing entecavir monotherapy to combination of entecavir plus tenofovir, we found that combination therapy did not result in statistically significant difference in virologic response compared to entecavir monotherapy. The BE-LOW study data confirmed the results of previous studies showing limited or no benefit of combination therapy compared to monotherapy for treatment-naïve patients with chronic hepatitis B,” said principal investigator Anna Lok, MD, FRCP, director of clinical hepatology and professor in the department of internal medicine at the University of Michigan Medical School in Ann Arbor.
Study Results
In this study, 379 nucleos(t)ide-naïve patients with CHB were randomized to receive either BARACLUDE (entecavir) 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Key findings at week 96 are:
A comparable proportion of patients in both treatment arms achieved the primary efficacy endpoint of HBV DNA
Among HBeAg-positive patients, the proportion achieving HBV DNA
Among HBeAg-negative patients, the proportion achieving HBV DNA
Secondary efficacy endpoints measured in the study included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, and HBeAg loss. ALT normalization was observed in 81.9% (149/182) of patients in this study in the BARACLUDE (entecavir) monotherapy arm versus 69% (136/197) in the BARACLUDE plus tenofovir arm. HBeAg seroconversion was observed in 32.5% (41/126) of patients in the BARACLUDE (entecavir) monotherapy arm versus 21.7% (30/138) in the BARACLUDE plus tenofovir arm in this study.
Two patients (1.1%) in the BARACLUDE monotherapy arm compared to five patients (2.5%) in the BARACLUDE plus tenofovir arm discontinued treatment prior to week 96. Patients who discontinued therapy prior to week 96 were considered treatment failures.
The overall adverse event profiles were similar across study arms. A total of three deaths occurred among treated patients, all on the BARACLUDE plus tenofovir arm: one due to bile duct tumor; one due to a late-onset exacerbation of hepatitis which was associated with breakthrough viremia while on continued treatment; and one due to cardiac arrest. One patient (0.5%) in the BARACLUDE monotherapy arm and two patients (1.0%) in the BARACLUDE plus tenofovir arm experienced on treatment ALT flares, defined as greater than 2 x baseline ALT and greater than 10 x ULN. No patients (0.0%) in either arm experienced off-treatment ALT flares. Six patients (3.3%) in the BARACLUDE monotherapy arm and four (2.0%) patients in the BARACLUDE plus tenofovir arm experienced serum creatinine increase ≥0.3 mg/dL. A total of five malignancies occurred among patients in the study: four (2.2%) patients in the BARACLUDE monotherapy arm and one (0.5%) patient in the BARACLUDE plus tenofovir arm. In the BARACLUDE monotherapy arm, there were three diagnoses of hepatocellular carcinoma (two on-treatment and one off-treatment) and one case of gastric cancer. In the BARACLUDE plus tenofovir arm there was one case of breast cancer.
Two patients (1.0%) in the BARACLUDE monotherapy arm and seven patients (3.6%) in the BARACLUDE plus tenofovir arm experienced virologic breakthrough. No recognized genotypic resistance mutations were observed in either treatment arm.
About The Study
The BE-LOW study is an open-label, multicenter, Phase IIIb study of 379 nucleos(t)ide-naïve patients with CHB. The patients were randomized 1:1 and treated with either BARACLUDE 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Nucleos(t)ide-naïve, HBeAg-negative CHB patient enrollment was capped at 30%. The primary efficacy endpoint was the proportion of patients with HBV DNA
About Chronic Hepatitis B
Approximately 350 million people worldwide are chronically infected with hepatitis B (approximately 5% of the world’s population) and 75% of these cases occur in the Asia-Pacific region.(2) Most people with chronic hepatitis B show no signs or symptoms, so many of those chronically infected are unaware of their status. A blood test can diagnose chronic hepatitis B. Patients should speak with their doctor about options available for this condition.
About BARACLUDE®
Discovered at Bristol-Myers Squibb, BARACLUDE® is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:
compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis
decompensated liver disease
For full prescribing information for BARACLUDE®, please consult the Summary of Product Characteristics.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
BARACLUDE® (entecavir) is a registered trademark of Bristol-Myers Squibb Company.
Contacts:
Bristol-Myers Squibb
Media: Annie Simond, +33 1 58 83 65 66, annie.simond(at)bms(dot)com
Note:
(1) HBV DNA carries the genetic blueprint of the hepatitis B virus. The number of HBV DNA “copies” found in a person’s blood, or “viral load,” indicates how rapidly the virus is reproducing in their liver. Low levels of HBV DNA, recognized as 300 copies per milliliter or less, indicate an “inactive” hepatitis B infection.
Reference:
(2) Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2:50 – 57. Available from http://www.medsci.org/v02p0050.htm Accessed November 2011
###
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Related Breast Cancer Prevention Press Releases
Winning Edge Designs Breast Cancer Prevention Rose Head CoverBreast Cancer Prevention Rose 460cc Golf Headcover Nice…
Day-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EA – Show your support for breast cancer research with a Pink Ribbon Desk Calendar Refill. Day-Timer contributes 10 percent of the proceeds to The Breast Cancer Research Foundation to achieve the prevention and cure of breast cancer. Pink Ribbon design on white 3-1/2″ x 6″ pages coordinates with other Pink Ribbon products. Each two-page-per-day offers hourly appointment times from 7 AM to 5 PM and past, currenDay-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EAShow your support for breast cancer re…
Breast Cancer: Risks and Prevention, Diagnosis & TreatmentsWhat are the risk factors for breast cancer and what decisions will a woman need to make on the basis of an abnormal mammogram res…
Categories: Breast Cancer Prevention Tags: , Arms, BARACLUDE, between, Combination, Comparison, Difference, entecavir, IIIb, Monotherapy, Phase, plus, Shows, Statistical, Study, Tenofovir, versus
Cancer treatment shows promise for rapid weight loss – Los Angeles Times
 HealthJockey.com |
Cancer treatment shows promise for rapid weight loss
Los Angeles Times A synthetic peptide that inhibits blood supply, a strategy employed in many cancer drugs, is found to kill fat cells and improve metabolic function in trials involving monkeys. By Melissa Healy, Los Angeles Times A drug born of a revolutionary approach … Drug helps fat monkeys slim down – are people next? Rapid weight loss possible through cancer drug? |
Artsmith, Inc. Men’s Embroidered Jacket Cancer Pink Ribbon Support Breast Cancer Awareness – Black, XLProduct Number: 030-544742285 Exercise your right to look great — and feel great — while on the go. Lightweight and easy to get …
24 PINK Ribbon BREAST CANCER Awareness Rubber Bracelets/HOPE/Strength/SURVIVOR/FAITH/New in Package/EXCELLENT for FUND RAISING24 Brand new in package PINK 8″ Rubber Bracelets imprinted with an assortment of different inspirations; COURAGE, DREAM, LOVE, HOP…
Artsmith, Inc. Women’s Embroidered Jacket Cancer Pink Ribbon Support Breast Cancer Awareness – 2XProduct Number: 030-544742276 Work up a good sweat while still looking great. Made for the fashion-conscious lady on the go, this …
Categories: Breast Cancer Awareness Tags: Angeles, Cancer, loss, promise, Rapid, Shows, Times, Treatment, Weight
Global Xigris (drotrecogin Alfa (activated)) Withdrawal After Study Shows No Survival Benefit
Eli Lilly is voluntarily withdrawing Xigris (drotrecogin alfa (activated)) from the market worldwide after a clinical trial (PROWESS-SHOCK trial) showed no survival benefit for sepsis and septic shock patients. In a Safety Announcement the US FDA (Food and Drug Administration) wrote that Xigris treatment should be stopped in patients being treated with the drug, and no new patients should be prescribed Xigris. Health care providers, clinics and hospitals have been asked to return any remaining Xigris stocks to their suppliers…
Health News from Medical News Today
Living ProofTop-rated Lifetime movie! Dr. Dennis Slamon has reached a breakthrough in his career. He has helped to develop a new experimental …
Wallmonkeys Peel and Stick Wall Decals – Breast Cancer in Dna Strands – 24″H x 23″W Removable GraphicWallMonkeys wall graphics are printed on the highest quality re-positionable, self-adhesive fabric paper. Each order is printed in…
Categories: Breast Cancer Drugs Tags: activated, after, Alfa, benefit, drotrecogin, Global, Shows, Study, Survival, Withdrawal, Xigris
Clinical Trial Shows Potential Benefit of HPV Vaccine for Anal Cancer
A vaccine used to prevent viral infections that cause cervical cancer also prevents similar infections of the anus that could eventually lead to anal cancer. The vaccine, Cervarix, protects women against infection with the two types of human papillomavirus (HPV) that cause the majority of anal and cervical cancers—types 16 and 18.
NCI Cancer Bulletin
Breast Cancer – Causes, Symptoms, Screening, Treatment Options, Life Expectancy and Natural RemediesBreast Cancer – Causes, Symptoms, Screening, Treatment Options, Life Expectancy and Natural RemediesThe complete and most compre…
Pink Ribbon Awareness Fox Run Cookie CutterFor your next Breast Cancer Bake Sale, fund raising or awareness event, use this pink plastic cookie cutter to make meaningful coo…
Categories: Breast Cancer Causes Tags: Anal, benefit, Cancer, Clinical, potential, Shows, Trial, Vaccine
Revolutionary three-dimensional model shows how breast tissue grows
Researchers have developed a revolutionary three-dimensional model that allows them to visualize how breast tissue grows in its earliest stages, giving them the closest look ever at the very beginnings of breast cancer.
ScienceDaily: Cancer News
For The Women We Love: A Breast Cancer Action Plan and Caregiver’s Guide for MenWhen a woman is diagnosed with breast cancer, it is vital that the men in their life move beyond traditional roles, adding new res…
When Your Wife Has Breast Cancer…: A Story of Love, Courage and SurvivalMark Weiss tells the story of his 38-year-old wife Cathy’s battle with breast cancer. It examines the choices they had, the decisi…
No More Secs!When 44 year-old Ann Pietrangelo is diagnosed with multiple sclerosis, all previous assumptions about health, work, and her new ro…
Categories: Breast Cancer Caregiver Tags: Breast, grows, Model, Revolutionary, Shows, threedimensional, tissue
Saffron Shows Promise In Preventing Liver Cancer
The full study of a new research indicating that Saffron has a significant chemopreventive effect against liver cancer in animals is published in the September issue of Hepatology, a journal published by Wiley Blackwell on behalf of the American Association for the Study of Liver Diseases…
Cancer / Oncology News From Medical News Today
Master Lock 1530DPNK Breast Cancer Research Foundation Dial Combination Lock, PinkMaster Lock Round Dial Combination PadlockShow your support and help find a cure for breast cancer; Aluminumcover with durable ano…
Alpen National Breast Cancer Foundation 10 x 42 Roof Prism BinocularAlpen Optics is the first optics company to partner with the National Breast Cancer Foundation with our new Pink Series Binocular …
Trudeau Mist 19-Ounce Hydrator Bottle, Breast Cancer Research Foundation PinkStay hydrated, stay hydrated, and stay hydrated. For physical and emotional well being, these are not merely words-of-wisdom, but …
Categories: Breast Cancer Foundation Tags: Cancer, Liver, Preventing, promise, Saffron, Shows
New non-invasive technology shows promise in shrinking liver tumors
A potential new option is beginning to emerge for patients with the fastest growing form of cancer in the United States, according to new research.
ScienceDaily: Cancer News
21st Century Understanding Cancer Toolkit: Life After Cancer Treatment, Valuable Advice and Support for Patients, Survivors, Families, Parents, Children, Caregivers, Young People, Advanced CancerThis massive compendium, with over 400 pages and eleven chapters, has authoritative information and practical advice from the nati…
Categories: Breast Cancer Caregiver Tags: Liver, noninvasive, promise, Shows, shrinking, technology, tumors
New Cancer Vaccine Shows Promise against Tumors in Mice
A series of intravenous (IV) vaccinations with a virus carrying fragments of DNA coding for normal human prostate tissue surface antigens cured cancer in about 80 percent of mice with established prostate tumors, new study findings showed.
NCI Cancer Bulletin
Breast Cancer: Causes, Diagnosis and Treatment (Cancer Etiology, Diagnosis and Treatments)Breast cancer is often initiated by abnormal cellular mechanisms and damage to DNA brought about by different types of cellular st…
Breast Cancer “Cause – Prevention – Cure”In 2006 the predecessor to this work, Breast Cancer “Prevention and Cure” Your Choice! was published and it received five-star r…
Breast Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages. Everything You Need to Know About Breast CancerThis book is for people who have breast cancer, as well as for their family members, friends, students, and others who want to fin…
Biomarker MIA shows presence of neurofibromas
Neurofibromatosis (NF1) is a genetic condition which affects one in every 3,000 people. New research shows that a simple blood test for the protein melanoma-inhibitory activity (MIA) could be used to indicate the presence of neurofibromas even if they cannot be seen.
ScienceDaily: Cancer News
Hanging Out With Lab Coats: Hope, Humor & Help for Cancer Patients and their CaregiversWendi Fox Pedicone became a cancer statistic in August 2004 when she was diagnosed with advanced stage breast cancer. With a treme…
21st Century Understanding Cancer Toolkit: Life After Cancer Treatment, Valuable Advice and Support for Patients, Survivors, Families, Parents, Children, Caregivers, Young People, Advanced CancerThis massive compendium, with over 400 pages and eleven chapters, has authoritative information and practical advice from the nati…
Categories: Breast Cancer Caregiver Tags: Biomarker, neurofibromas, presence, Shows
Combination antibody therapy shows promise in metastatic melanoma
A duo of monoclonal antibodies — ipilimumab and bevacizumab — each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial.
ScienceDaily: Cancer News
21st Century Understanding Cancer Toolkit: Life After Cancer Treatment, Valuable Advice and Support for Patients, Survivors, Families, Parents, Children, Caregivers, Young People, Advanced CancerThis massive compendium, with over 400 pages and eleven chapters, has authoritative information and practical advice from the nati…
Surviving Your Wife’s Cancer: A Guide For Husbands Whose Wives Have Been Diagnosed With CancerStan Scott lost his wife to sarcoma in 1991. Realizing that many men were going through the same emotional and physical trauma he …
Categories: Breast Cancer Caregiver Tags: Antibody, Combination, melanoma, metastatic, promise, Shows, therapy
